All
Quality Agreements and Out-of-Specification Investigations
June 2nd 2019A good working relationship between sponsor and contractor will become invaluable when an OOS occurs, says Susan J. Schniepp, executive vice-president of post-approval pharma and distinguished fellow, Regulatory Compliance Associates.
Heritage Pharmaceuticals Inc. Recalls Products Due to Sterility Failure
May 30th 2019The company is voluntarily recalling Amikacin Sulfate Injection, USP, 1g/4 mL (250mg/mL), and Prochlorperazine Edisylate Injection, USP, 10mg/2mL (5mg/mL), to the consumer level because microbial growth was detected.
FDA Publishes Guidance on Therapeutic Protein Biosimilars
May 22nd 2019The guidance discusses the design and evaluation of comparative analytical studies used to support the biosimilarity of a proposed therapeutic protein product to a reference product licensed under section 351(a) of the Public Health Service Act.